Michael Robert A. 4

4 · AbbVie Inc. · Filed Mar 1, 2024

Form 4

Period: 2024-02-28

DirectorCHAIRMAN OF THE BOARD AND CEO

Transactions

Tax Payment
Common Stock, $0.01 par value
2024-02-28$178.99/sh−37,638$6,736,826→ 145,964 total
Exercise/Conversion
Common Stock, $0.01 par value
2024-02-29$61.36/sh+11,420$700,731→ 157,384 total
Sale
Common Stock, $0.01 par value
2024-02-29$176.46/sh−47,319$8,349,911→ 98,645 total
Exercise/Conversion
Common Stock, $0.01 par value
2024-02-29$54.86/sh+10,140$556,280→ 167,524 total
Sale
Common Stock, $0.01 par value
2024-02-29$176.44/sh−21,560$3,804,046→ 145,964 total
Exercise/Conversion
Option (Right to Buy)
2024-02-29$61.36/sh−11,420$700,731→ 0 total
Exercise: $61.36From: 2018-02-16Exp: 2027-02-15→ Common Stock (11,420 underlying)
Exercise/Conversion
Option (Right to Buy)
2024-02-29$54.86/sh−10,140$556,280→ 0 total
Exercise: $54.86From: 2017-02-18Exp: 2026-02-17→ Common Stock (10,140 underlying)

Footnotes (3)

[F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.39 to $176.57, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.42 to $176.60, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.

Documents

1 file